You are using an outdated browser and your browsing experience will not be optimal. Please update to the latest version of Microsoft Edge, Google Chrome or Mozilla Firefox. Install Microsoft Edge

June 11, 2024

Genome Editing in Thai and Indonesian Agricultural Biotechnology

Advances in biotechnology have enabled the development of a range of new agricultural tools. From DNA sequencing to plant tissue culture and gene editing, these advances are facilitating the development of better crops.

Genetically modified organisms (GMOs) are one well-known example of agricultural biotechnology. GMOs are organisms whose genetic material has been artificially altered by inserting a piece of foreign DNA. This DNA may be synthetic in origin or sourced from other organisms.

Genome editing (also called gene editing or GEd) involves making precise changes to an organism’s genome without the integration of foreign DNA elements. Several approaches to genome editing have been developed. A well-known one is called CRISPR-Cas9, in which scientists make precise “cuts” in the DNA to create a new genetic variation. Unlike with GMOs, this introduces only minor modifications that are indistinguishable from natural mutations, typically by transplanting genes that code desirable traits from one species into another.

GEd technology has been recognized and supported by the Food and Agriculture Organization of the United Nations (FAO). Thirteen FAO-member countries who are also members of the Organization for Economic Cooperation and Development (OECD) announced their support of the use of GEd technology for commercial uses and consumption at a recent WTO meeting. In addition, over 40 countries around the world, such as Argentina, Australia, Brazil, Canada, Chile, China, England, Japan, Kenya, the Philippines, Russia, the UK, and the US, have published policies emphasizing that foods free of transgenes (i.e., foods that do not contain genes transferred from external sources) are not GMOs, concluding that GEd plants are as safe as normal plants.

In February 2024, the European Parliament approved new genomic techniques (NGTs), or GEd. As a result, plants that are produced using GEd technology are not classified by the EU as GMOs, and the EU authorities consider them to be the same as conventional plants.

Thailand’s Stance toward GEd

In Thailand, the Department of Agriculture in the Ministry of Agriculture and Cooperatives (MOAC) views the results of the EU vote as providing timely support for Thailand’s own policy consideration of the issue. The European Parliament has agreed that genome editing technology is highly safe for human health and the environment, and its use can potentially reduce costs and increase the quality and productivity of agriculture. With this development, it is an opportune time for Thailand to accelerate the process of adopting GEd technology in the agricultural sector for food safety and security by drafting guidelines for the application of GEd technology.

Since the beginning of 2024, the MOAC has taken several actions targeting the development of GEd knowledge.

One event the Department of Agriculture organized was a seminar titled “Modern Biotechnology to Solve the Global Crisis and Emerging Pests.” This event was a brainstorming seminar for all stakeholders on how to take advantage of technology that is safe and on par with other countries, as well as creating guidelines for operating and driving GEd technology in Thailand, including communicating with the public and consumers for a better understanding of the safety of GEd technology and its difference from the production of GMOs. The seminar emphasized that Thailand must be able to take advantage of GEd technology in its future planning for addressing global crises and emerging pests that will impact its agricultural sector.

The Department of Agriculture also organized an academic seminar on GEd technology to set a clear national stance on the issue and accelerate communication with the public and consumers that plants produced with GEd technology are different from GMOs. Next, the Department of Agriculture will invite experts from the FAO, from various countries such as Australia, Japan, and the United States, and from the private and public sectors to join together in a push to build confidence in GEd technology and speed up the preparation of operational procedures. Doing so will assist Thailand in leveraging genome editing technology for the agricultural sector for food safety and security through modern biotechnology. The experts mentioned above recognize that NGTs, or GEd, are likely to continue playing an important role in the increasingly dire situations of global warming and global food crises.

Most professionals believe that using GEd technology to modify the genetics of groups of plants that can be naturally hybridized can produce high-yielding plant varieties that are resistant to disease and drought. In addition, they believe that GEd technology will increase nutritional value. Most countries in the world have invested in research into GEd and approved the use of GEd technology, accepting GEd technology for both commercial and consumption purposes, as with conventional crops, to increase national food security.

Early Support for GEd in Thailand

Though the Ministry of Agriculture and Cooperatives in Thailand has not yet issued any draft notifications or announced public hearings regarding the use of GEd, there is progress in the public sector. One project showing that Thailand is ready to support the use of GEd technology was launched when the National Center for Genetic Engineering and Biotechnology (BIOTEC) released a publication looking at the issue of genome editing and providing technical criteria for considering organisms developed with GEd technology.

Under the guidelines, genome-edited plants derived from the use of GEd techniques employing site-directed nucleases (SDNs) are generally classified into three categories:

  • SDN-1 (deletion), site-directed mutagenesis without using a DNA sequence template.;
  • SDN-2 (substitution), site-directed mutagenesis using a DNA sequence template.; and
  • SDN-3 (insertion), site-directed insertion of a gene/large DNA sequence using a DNA sequence template.

The guidelines have not set out criteria for considering organisms developed with genome-editing technology that do not qualify as living beings genetically modified.

In the view of BIOTEC, SDN-1 plants are not considered to be GMOs, while SDN-2 and SDN-3 plants may be considered as such. If a party wishes to use GEd in conjunction with food, a safety assessment by BIOTEC will be required. The required safety assessment for SDN-1 is lower than for SDN-2 and SDN-3.

This is a positive sign showing that Thailand is ready to move forward with GEd technology development. We may see wider discussions, acceptance, and regulations regarding GEd technology in the future.

Indonesia’s Stance toward GEd

In recent discussions on GEd technology, Indonesian authorities agreed that the determination of whether or not genome-edited products are considered genetically modified will be based on the mechanism of genetic repair, in accordance with the definitions set forth in the Cartagena Protocol and Government Regulation No. 21 of 2005 regarding Biosafety of Genetically Modified Products. If the repair mechanism is carried out by involving donors or genes that do not have a taxonomic relationship with the organism that is the subject of the GEd, the genome-edited product is considered genetically modified. However, if it does not involve a donor or genes outside the individual, it can be considered non-genetically modified.

Despite the discussions surrounding genome editing, there are not yet any specific regulations on genome editing in Indonesia. Therefore, based on Government Regulation No. 21 of 2005 regarding Biosafety of Genetically Modified Products, GEd is still considered genetic modification, and genome-edited products must undergo a safety assessment in order to obtain approval from the Biosafety Commission.

The safety assessment procedure for genetically modified food products is overseen by Indonesia’s National Agency of Drug and Food Control, or BPOM, and involves the following steps:

  • Application submission. Applications are submitted through BPOM’s e-filing system. Applicants must also submit supporting documents in accordance with the relevant BPOM regulations regarding genetically modified food products, accompanied by an integrity pact.
  • Data verification process. If the application is not complete, the applicant must supply the required materials within 14 days of receiving notification from the head of BPOM.
  • Biosafety commission assignment. The head of BPOM assigns the Biosafety Commission to conduct a food safety assessment. The Biosafety Commission has the task of providing recommendations to the authorized minister and the head of the authorized non-ministerial government institution (LPNK) in formulating and establishing policies and issuing biosafety certificates for genetically modified products.
  • Assessment by Biosafety Commission. The Biosafety Commission conducts the food safety assessment within 14 days.
  • Assessment by Biosafety Technical Team. The Biosafety Commission may assign the Biosafety Technical Team, which assists the Biosafety Commission in conducting evaluations and technical assessments of biosafety, to conduct a technical document review and perform further testing if necessary. This will be completed within 56 days of receiving the assignment letter from the Biosafety Commission.
  • Technical assessment results. The Biosafety Technical Team submits the results of the technical assessment to the Biosafety Commission within 7 days.
  • Assessment submission to Biosafety Clearing House. The Biosafety Commission submits the technical assessment of the Biosafety Technical Team to the Biosafety Clearing House, a Biosafety Commission tool that serves as a means of communication between the Biosafety Commission and stakeholders, within 15 days.
  • Publication by Biosafety Clearing House. The Biosafety Clearing House publishes a summary of the Biosafety Technical Team’s technical assessment for 60 days to allow the public to comment.
  • Report submission to Biosafety Commission. The Biosafety Clearing House then submits a public response report to the Biosafety Commission.
  • Biosafety Commission recommendation. The Biosafety Commission submits a food safety recommendation to the head of BPOM within 14 days. In submitting recommendations on food safety of Genetically Modified Products to the Head BPOM, taking into account the results of the assessment of the Biosafety Commission Technical Team and input from the public.
  • Issuance of approval by Head of BPOM. The head of BPOM issues a safety certificate and permit for the distribution of the genetically modified food.

Conclusion

As the regulatory landscapes continue to evolve around genome editing technologies in Thailand, Indonesia, and across the globe, businesses operating in the agricultural biotechnology sector must stay vigilant. Navigating the emerging regulations and approval processes will be crucial for companies looking to commercialize new genome-edited crops and food products. Companies must also carefully manage public perception around genome editing, clearly communicating the science and safety assessments behind these innovations. With strategic foresight and regulatory attentiveness, the agricultural biotech industry can capitalize on the promise of genome editing to enhance food security and drive sustainable productivity gains. Businesses primed to leverage genome editing technologies while mitigating regulatory risks will be positioned for leadership in this new age of agricultural biotechnology.

RELATED INSIGHTS​ 

June 17, 2026
Thailand’s new labeling requirements for medical devices, which include for the first time a unique device identification (UDI) requirement for software as a medical device (SaMD), take effect on June 20, 2026. The Notification of the Ministry of Public Health regarding Criteria, Methods, and Conditions on Labeling and Instructions for Use for Medical Devices 2025, which replaces a similar notification from 2020, was published in the Government Gazette on December 22, 2025. To ensure clarity, modernity, and patient safety, the regulation requires domestic manufacturers and importers to provide labels and instructions for use (IFU) that are clearly legible, complete, and free of false or misleading claims. It also permits IFU to be provided in electronic format, such as via QR codes, websites, or other digital channels—directly relevant to SaMD, where physical labels are impractical and electronic presentation is the natural medium. The notification distinguishes two categories for labeling language. Home-use medical devices (for lay users outside healthcare facilities) must have labels and IFU in Thai. Professional-use medical devices may display labels and documentation in either Thai or English. This distinction is significant for SaMD developers: software intended for clinical professionals may use English-language interfaces and IFU, while consumer-facing health applications must provide Thai-language content. Labeling and UDI Requirements Labels and IFU must include, at a minimum: Product name and intended purpose Quantity or volume Name and address of domestic manufacturer or importer Thai FDA approval number Lot, version, or serial number Manufacturing date and expiry date For SaMD, the version number requirement is particularly relevant. The regulation also mandates display of a UDI code for SaMD in risk category 2 (moderate-risk), category 3 (moderate- to high-risk), and category 4 (high-risk), according to Thailand’s medical device risk classification system (which complies with the ASEAN Medical Device Directive and the EU
June 5, 2026
On May 25, 2026, Vietnam’s Ministry of Health issued Circular No. 16/2026/TT-BYT governing free-of-charge medicine support programs for medical establishments (Circular 16). Circular 16 will take effect on July 10, 2026, replacing Circular No. 31/2018/TT-BYT, which currently regulates the same subject matter. Circular 16 introduces several significant changes compared to the existing legal framework. Removal of Prior Approval Requirement Under the current regulations, free-of-charge medicine support programs are divided into two categories: (1) entirely free-of-charge provision of medicines for all types of drugs and (2) partially free-of-charge provision applicable only to brand-name drugs under patent protection or drugs whose generic products with identical active ingredients and dosage forms are available in Vietnam. Under the current regulations, partially free-of-charge programs are subject to mandatory registration with the competent authority, while entirely free-of-charge programs could be implemented without prior approval. A key reform under Circular 16 is that it stipulates only entirely free-of-charge medicine support programs applicable to all types of medicines, thereby eliminating the partially free-of-charge category. In addition, free-of-charge medicine support programs may be carried out solely based on a written agreement between the pharmaceutical company and the medical establishment, without any requirement for prior approval from competent authorities prior to implementation. Written Agreement Requirements Circular 16 requires the pharmaceutical company and medical establishment to enter into a written agreement in accordance with a prescribed template. This agreement must include the following compulsory information: Information on the supported medicines Form of support (entirely free-of-charge provision to patients) Quantity of medicines provided Target patient groups and applicable indications Duration of the program Rights and obligations of each party Transitional provisions on the protection of patients’ rights upon completion of the program The agreement may contain other contents as agreed by the parties, provided that these do not contradict applicable laws.
June 4, 2026
Indonesia’s Minister of Health has issued Decree No. HK.01.07/MENKES/301/2026 on the Affixation of Nutritional Labels and Health Information to Ready-to-Eat Processed Food Products. The decree came into force on April 14, 2026, and was issued to implement the Health Law and Minister of Health Regulation No. 3 of 2026 on Disease Control. The decree requires the inclusion of Nutri-Level labeling on the front-of-pack nutrition labeling (FOPNL) to indicate the product’s nutritional level based on the content of sugar, salt, and fat (“gula, garam dan lemak (GGL)”). Changes from 2024 Draft Regulation The Nutri-Level labeling was previously proposed in 2024 by the Indonesian FDA (BPOM) through a draft regulation concerning nutrition information. While the categories of Nutri-Level labeling remain the same in the issued decree, the content requirements of sugar, salt and fat in the decree are different from the earlier proposal introduced in the 2024 draft BPOM regulation. In addition, the decree has further specified that the content of fat in the Nutri-Level labeling is the content of saturated fat, not total fat as previously proposed in the 2024 draft. The decree requires Nutri-Level labeling to be implemented in beverage products, which is the same as previously proposed in the 2024 draft BPOM regulation. Other food products may gradually become subject to mandatory Nutri-Level labeling under future implementing regulations. Nutri-Level Labeling Food levels as shown by the Nutri-Level labeling are classified into four color-coded categories from A to D: Level A (lowest amount) in dark green Level B in light green Level C in yellow Level D (highest amount) in red The Nutri-Level labeling is represented by the following image. The requirements for each level for sugar, salt, and fat content, based on amounts per 100 milliliters of product in beverage form, are as follows. Nutri-Level information must be
May 29, 2026
Indonesia’s Food and Drug Authority (BPOM) has issued Regulation No. 7 of 2026 on Drug Promotion and Advertising, establishing an updated framework for promotional activities involving medicinal products in Indonesia. The regulation took effect on April 16, 2026, and supersedes BPOM Regulation No. 2 of 2021 on Drug Advertising Supervision. The new regulation maintains general principles for advertising content, including requirements that advertisements be objective, complete, and not misleading, as further detailed in its annex. It also confirms that advertisements for nonprescription drugs directed to the public must obtain prior approval from BPOM before publication and must be in Bahasa Indonesia. The regulation provides a more comprehensive framework governing how drug promotion is conducted, introducing several notable additions and changes, as described below. Procedure and Requirements for Drug Advertisement Approval To apply for a drug advertisement approval, applicants must create an online account through the dedicated portal SIAPIK. Advertisement approval is available only for registered drugs; unregistered drugs are not eligible for advertisement approval with BPOM. The application must include the advertisement design, along with a translation if the design contains any wording in a foreign language. The submission format varies by media type, requiring, for example, copies in the form of print advertisements for visual media, scripts for audio media, and storyboards for audiovisual media. For online media—including social media—submissions should include any captions, descriptions, and hashtags that form an integral part of the advertising material. The approval timeline takes approximately 3–4 months, as BPOM will generally request additional information or revisions during the verification and evaluation process. Applicants have 20 days to submit any such requested documents. BPOM may also conduct a reevaluation of advertisements that have already received approval, based on monitoring results or new information regarding the safety and quality of the advertised drug. This